Medtronic
Global medical device and healthcare technology manufacturer.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Medtronic plc
- Entity type
- COMPANY
- Founded
- 1949
- Headquarters
- Ireland
- Company size
- >5,000
- Market role
- Advertiser / Brand
- Ticker
- MDT
- Official website
- medtronic.com
What Medtronic does
Medtronic operates a diversified medical technology model built around designing, manufacturing, and commercialising medical devices and therapies for clinical use. It creates value by supplying essential products used in diagnosis, treatment, monitoring, and surgical intervention, then monetises through product sales into healthcare procurement channels and long-term institutional relationships.
Category differentiation
Medtronic is a medical technology manufacturer, not an advertising, media, or marketing software company. It sells clinical devices and therapies to healthcare buyers rather than digital marketing infrastructure.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Medtronic plc is a publicly listed healthcare technology company headquartered in Ireland. It develops, manufactures, and sells medical devices and therapy systems used by hospitals, clinicians, and health systems across multiple care areas. The business is not an adtech, martech, or media company; it is a large-scale medtech manufacturer and commercial operator. The company generates revenue primarily from the sale of medical devices, procedure-related products, and therapy platforms to healthcare providers and institutional buyers. Its customer base is predominantly enterprise healthcare organisations, with downstream patient impact through the use of its products in clinical settings. Its public listing, long operating history, and large workforce position it as an established global incumbent rather than a high-growth software pure play.
Company news briefing
Briefing updated:
Medtronic is advancing structural changes through an exchange offer to complete the separation of MiniMed Group, Inc., alongside ongoing financial reporting reflected in its recent 10-Q filing and a second-quarter fiscal year 2027 cash dividend of $0.72 per ordinary share. Additionally, the company's regional communications and marketing support is being reinforced via FINN Partners' new Minneapolis office, which services key local clients including Medtronic.
Business model & monetisation
Medtronic monetises primarily through one-time and repeat sales of medical devices, implantable products, therapy systems, and procedure-linked clinical technologies. Commercial revenue is driven by enterprise healthcare procurement, long sales cycles, and ongoing replacement or utilisation of device-related products within care delivery settings.
- Medical devices and therapy systems
- One-time product sales to healthcare providers and institutions
Products & capabilities
No products with linked sources are available in this view.
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Recorded impact score: 4.5/5
Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed. Provides Medtronic shareholders with option for a generally tax-free exchange for U.S. federal income tax...
FINN Partners Opens Minneapolis Office, Expanding Midwest Presence
Corporate Expansion · Recorded impact score: 1/5
FINN Partners, a global independent marketing and communications firm, has opened a new office in Minneapolis, its fifth location in the Midwest and 39th worldwide. The office is staffed by a 10-person team and led by four senior partners: Greg Swan, Laura Anderson Sanchez, Carrie Young, and David Krejci. The team will serve clients including Hormel Foods, Medtronic, and Life Time. The expansion reflects FINN's growth in the region and its focus on integrated services such as social, influencer, digital marketing, and Generative Engine Optimization (GEO) to help brands gain visibility in AI-driven search environments. Dan Pooley, Founding Managing Partner for the Midwest, oversees the new office.
- FINN Partners opened a new office in Minneapolis, its fifth in the Midwest and 39th worldwide.
- The office has a 10-person team supported by four senior partners.
10-Q Financial Filing Analysis for Medtronic (2026-09-03)
financials · Recorded impact score: 4.3/5
Medtronic plc reported net sales of $9.756 billion for Q1 FY2027 (ended July 31, 2026), marking a 14% year-over-year increase supported by broad segment growth and an additional fiscal week. The company actively expanded its neuroscience portfolio through strategic acquisitions of Scientia Vascular ($681 million) and SPR Therapeutics ($654 million). Additionally, Medtronic advanced the full divestiture of its remaining stake in MiniMed Group following its March 2026 IPO, and executed post-quarter strategic transactions including a $700 million investment in Cornerstone Robotics and a $1.0 billion cross-currency swap. However, the company faces material legal headwinds, actively contesting a $382 million antitrust verdict (subject to trebling) and an $88 million product liability award.
- Net sales rose 14% year-over-year to $9.756 billion for Q1 FY2027, aided by portfolio growth and an extra week in the fiscal quarter.
- Completed $1.335 billion in aggregate acquisitions—Scientia Vascular for $681 million and SPR Therapeutics for $654 million—alongside a subsequent $700 million investment in Cornerstone Robotics.
Medtronic announces cash dividend for second quarter of fiscal year 2027
Recorded impact score: 5/5
The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This...
Explore company relationships
Questions about Medtronic
What is Medtronic?
Medtronic is a publicly listed healthcare technology company that develops and sells medical devices and therapy systems.
Who uses Medtronic?
Hospitals, health systems, clinics, surgeons, and other healthcare providers use Medtronic products in patient care.
How does Medtronic make money?
Medtronic makes money primarily by selling medical devices, implantable products, and therapy platforms to healthcare institutions.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
6 publicly documented primary sources and citations linked across the market graph.
Continue your research on Medtronic
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.